Altimmune, Inc. (ALT)
US — Healthcare Sector
Automate Your Wheel Strategy on ALT
With Tiblio's Option Bot, you can configure your own wheel strategy including ALT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALT
- Rev/Share 0.0002
- Book/Share 2.0757
- PB 1.8789
- Debt/Equity 0.0
- CurrentRatio 17.1835
- ROIC -0.4359
- MktCap 344203470.0
- FreeCF/Share -0.7422
- PFCF -5.1868
- PE -4.1558
- Debt/Assets 0.0
- DivYield 0
- ROE -0.5479
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ALT | Goldman | -- | Sell | -- | $1 | July 10, 2025 |
| Initiation | ALT | William Blair | -- | Market Perform | -- | -- | Feb. 28, 2025 |
| Initiation | ALT | Stifel | -- | Buy | -- | $18 | Jan. 8, 2025 |
News
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH
ALT
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH (metabolic dysfunction-associated steatohepatitis). Pemvidutide has successfully completed a Phase 1 trial for a related liver disease but has yet to demonstrate efficacy in the target indication of MASH.
Read More
About Altimmune, Inc. (ALT)
- IPO Date 2017-05-26
- Website https://altimmune.com
- Industry Biotechnology
- CEO Vipin K. Garg
- Employees 59
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.